Hesperidin-Diosmin Effect on Metabolic Syndrome and Diabetic Neuropathy Among Patients With Type 2 Diabetes Mellitus
Led by Beni-Suef University · Updated on 2022-02-17
129
Participants Needed
1
Research Sites
49 weeks
Total Duration
On this page
AI-Summary
Brief Title
Who Can Participate
Trial Site Locations
How is the study designed?
Research Publications
AI-Summary
What this Trial Is About
The components of metabolic syndrome (MetS), particularly obesity and dyslipidemia, are linked to peripheral neuropathy (PN) among patients with diabetes or even without diabetes. Several studies revealed that complementary and herbal medicine could provide a potential for PN management and MetS components. Thus, designing clinical trials with interventions combinations to achieve a considerable improvement is highly recommended. Hesperidin and diosmin, citrus-derived flavonoids, have been reported to possess anti-hyperlipidemic, anti-inflammatory, analgesic, antioxidant, antidiabetic, and anti-hypertensive effect with high tolerability and safety profile
CONDITIONS
Brief Title
Hesperidin and Diosmin Effect on Metabolic Syndrome
Who Can Participate
Age: 18Years - 70Years
All Genders
Eligibility Criteria
You may qualify if you...
Type 2 diabetes adult patients who meet metabolic syndrome criteria and with diabetic neuropathy
You will not qualify if you...
patients without any parameter of inclusion criteria
Trial Site Locations
Total: 1 location
1
University
Al Fayyum, Egypt, 13556
Status Unknown
Loading map...
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
The Effect of Hesperidin and Diosmin Individually or in Combination on Metabolic Profile and Neuropathy among Diabetic Patients with Metabolic Syndrome: A Randomized Controlled Trial.
Hasnaa Osama, Ehdaa O Hamed, Muhammed A Mahmoud...